BeviprexTM

Glycopyrronium Bromide + Formoterol Fumarate
Anticholinergic + Beta-2 stimulant (Antiasthma)

Indication:

For the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and/or emphysema.

Dosage & Administration:

Adults: Should be administered 2 puffs twice daily, in the morning and in the evening.

Preparation:

BeviprexTM HFA Inhaler: Each puff delivers Glycopyrronium Bromide 9 mcg and Formoterol Fumarate 4.8 mcg. Each Inhaler delivers 120 puffs.